StockData
AstraZeneca PLC logo

AstraZeneca PLC

AZNNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Score 12/30
$163.95−1.46 (-0.88%)

Close on Oct 19, 2026Market cap $255.76BP/E 25.1Yield 1.91%

AstraZeneca Saphnelo (anifrolumab) by Quarter

Saphnelo (anifrolumab) — Emerging Markets product sales ($M) ($M)

QuarterlyAnnual

AstraZeneca Saphnelo (anifrolumab): $7M in Q2 2026, up 75.0% from a year earlier. That is the highest of the 20 quarters on record here.

Latest, Q2 2026
7
Period ended Jun 30, 2026
Change on a year earlier
+75.0%
4 in Q2 2025
History
20 quarters
Since Q3 2021
Sources
20
Documents cited below

Where the Q2 2026 figure comes from

“|| Saphnelo | | 209 | | 25 | | 24 | | 175 | | 21 | | 7 | | 68 | | 64 | | 19 | | 58 | | 51 | | 8 | | 31 | | 38”

Source: Form 6-K FY2026Q2 Earnings Release ↗

Reported in Form 6-K / 20-F Product Sales Table.

Quarterly history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedSaphnelo (anifrolumab) — Emerging Markets product sales ($M) ($M)Year on yearSource
Q2 2026Jun 30, 20267+75.0%Form 6-K FY2026Q2 Earnings Release ↗
Q1 2026Mar 31, 20265+66.7%Form 6-K FY2026Q1 Earnings Release ↗
Q4 2025Dec 31, 20256+200.0%Form 6-K FY2025Q4 Earnings Release ↗
Q3 2025Sep 30, 20254+33.3%Form 6-K FY2025Q3 Earnings Release ↗
Q2 2025Jun 30, 20254+300.0%Form 6-K FY2025Q2 Earnings Release ↗
Q1 2025Mar 31, 20253+200.0%Form 6-K FY2025Q1 Earnings Release ↗
Q4 2024Dec 31, 20242+100.0%Form 6-K FY2024Q4 Earnings Release ↗
Q3 2024Sep 30, 20243–Form 6-K FY2024Q3 Earnings Release ↗
Q2 2024Jun 30, 202410.0%Form 6-K FY2024Q2 Earnings Release ↗
Q1 2024Mar 31, 20241–Form 6-K FY2024Q1 Earnings Release ↗
Q4 2023Dec 31, 20231–Form 6-K FY2023Q4 Earnings Release ↗
Q3 2023Sep 30, 20230–Form 6-K FY2023Q3 Earnings Release ↗
Q2 2023Jun 30, 20231–Form 6-K FY2023Q2 Earnings Release ↗
Q1 2023Mar 31, 20230–Form 6-K FY2023Q1 Earnings Release ↗
Q4 2022Dec 31, 20220–Form 6-K FY2022Q4 Earnings Release ↗
Q3 2022Sep 30, 20220–Form 6-K FY2022Q3 Earnings Release ↗

Cite this data

StockData. (2026). AstraZeneca Saphnelo (anifrolumab) ($M), quarterly Q3 2021–Q2 2026 [Data set]. Compiled from AstraZeneca SEC filings and investor materials. https://stockdatahq.com/stocks/azn/kpis/med-saphnelo-em

See every metric in the AstraZeneca KPI table. Data updated Oct 28, 2026.